Together, these results indicate that A33+ Li-EVs prevented the development of murine IBD through TGF-β1 signalling, and higher levels of TGF-β1, but not other factors determined the enhanced efficacy of IBD-A33+ Li-EVs to prevent IBD development. Here, TGFB1 is linked to inflammatory bowel disease.